What is Lucid Diagnostics?
Lucid Diagnostics Inc. is dedicated to combating highly lethal esophageal adenocarcinoma (EAC) by focusing on patients with gastroesophageal reflux disease (GERD) who are at elevated risk. The company's core offering includes the EsoGuard Esophageal DNA Test, which is utilized with the EsoCheck Esophageal Cell collection device. This integrated system is designed for the early detection of esophageal precancer, with the ultimate goal of preventing EAC-related fatalities. Established in 2018 and headquartered in New York, New York, Lucid Diagnostics operates as a subsidiary of PAVmed Inc., positioning itself within a broader healthcare innovation ecosystem.
How much funding has Lucid Diagnostics raised?
Lucid Diagnostics has raised a total of $85.3M across 2 funding rounds:
Stock Offering
$70M
Stock Offering
$15.3M
Stock Issuance/Offering (2021): $70M, investors not publicly disclosed
Stock Issuance/Offering (2025): $15.3M, investors not publicly disclosed
What's next for Lucid Diagnostics?
With the infusion of $15.3M in a major strategic investment, Lucid Diagnostics is poised for significant expansion. This capital injection, contributing to a total funding base of $85.3M, will likely fuel the scaling of its commercial operations, further development of its diagnostic platform, and broader market penetration. The company's focus on early detection for a high-risk patient population aligns with growing healthcare trends towards preventative medicine, suggesting a strong trajectory for future growth and potential strategic partnerships within the medical technology landscape.
See full Lucid Diagnostics company page
